Optimizing a therapeutic humanized follicle‐stimulating hormone–blocking antibody formulation by protein thermal shift assay. Issue 1 (11th January 2023)
- Record Type:
- Journal Article
- Title:
- Optimizing a therapeutic humanized follicle‐stimulating hormone–blocking antibody formulation by protein thermal shift assay. Issue 1 (11th January 2023)
- Main Title:
- Optimizing a therapeutic humanized follicle‐stimulating hormone–blocking antibody formulation by protein thermal shift assay
- Authors:
- Sant, Damini
Rojekar, Satish
Gera, Sakshi
Pallapati, Anusha R.
Gimenez‐Roig, Judit
Kuo, Tan‐Chun
Padilla, Ashley
Korkmaz, Funda
Cullen, Liam
Chatterjee, Jiya
Shelly, Eleanor
Meseck, Marcia
Miyashita, Sari
Macdonald, Anne
Sultana, Farhath
Barak, Orly
Ryu, Vitaly
Kim, Se‐Min
Robinson, Cemre
Rosen, Clifford J.
Caminis, John
Lizneva, Daria
Haider, Shozeb
Yuen, Tony
Zaidi, Mone - Abstract:
- Abstract: Biopharmaceutical products are formulated using several Food and Drug Administration (FDA) approved excipients within the inactive ingredient limit to maintain their storage stability and shelf life. Here, we have screened and optimized different sets of excipient combinations to yield a thermally stable formulation for the humanized follicle‐stimulating hormone (FSH)–blocking antibody, MS‐Hu6. We used a protein thermal shift assay in which rising temperatures resulted in the maximal unfolding of the protein at the melting temperature ( T m ). To determine the buffer and pH for a stable solution, four different buffers with a pH range from 3 to 8 were screened. This resulted in maximal T m s at pH 5.62 for Fab in phosphate buffer and at pH 6.85 for Fc in histidine buffer. Upon testing a range of salt concentrations, MS‐Hu6 was found to be more stable at lower concentrations, likely due to reduced hydrophobic effects. Molecular dynamics simulations revealed a higher root‐mean‐square deviation with 1 mM than with 100 mM salt, indicating enhanced stability, as noted experimentally. Among the stabilizers tested, Tween 20 was found to yield the highest T m and reversed the salt effect. Among several polyols/sugars, trehalose and sucrose were found to produce higher thermal stabilities. Finally, binding of recombinant human FSH to MS‐Hu6 in a final formulation (20 mM phosphate buffer, 1 mM NaCl, 0.001% w/v Tween 20, and 260 mM trehalose) resulted in a thermal shiftAbstract: Biopharmaceutical products are formulated using several Food and Drug Administration (FDA) approved excipients within the inactive ingredient limit to maintain their storage stability and shelf life. Here, we have screened and optimized different sets of excipient combinations to yield a thermally stable formulation for the humanized follicle‐stimulating hormone (FSH)–blocking antibody, MS‐Hu6. We used a protein thermal shift assay in which rising temperatures resulted in the maximal unfolding of the protein at the melting temperature ( T m ). To determine the buffer and pH for a stable solution, four different buffers with a pH range from 3 to 8 were screened. This resulted in maximal T m s at pH 5.62 for Fab in phosphate buffer and at pH 6.85 for Fc in histidine buffer. Upon testing a range of salt concentrations, MS‐Hu6 was found to be more stable at lower concentrations, likely due to reduced hydrophobic effects. Molecular dynamics simulations revealed a higher root‐mean‐square deviation with 1 mM than with 100 mM salt, indicating enhanced stability, as noted experimentally. Among the stabilizers tested, Tween 20 was found to yield the highest T m and reversed the salt effect. Among several polyols/sugars, trehalose and sucrose were found to produce higher thermal stabilities. Finally, binding of recombinant human FSH to MS‐Hu6 in a final formulation (20 mM phosphate buffer, 1 mM NaCl, 0.001% w/v Tween 20, and 260 mM trehalose) resulted in a thermal shift (increase in T m ) for the Fab, but expectedly not in the Fc domain. Given that we used a low dose of MS‐Hu6 (1 μM), the next challenge would be to determine whether 100‐fold higher, industry‐standard concentrations are equally stable. Abstract : Here, we have screened and optimized different sets of excipient combinations to yield a thermally stable formulation for the humanized follicle‐stimulating hormone (FSH)–blocking antibody, MS‐Hu6. We used a protein thermal shift assay in which rising temperatures resulted in maximal unfolding of protein at the melting temperature ( T m ). … (more)
- Is Part Of:
- Annals of the New York Academy of Sciences. Volume 1521:Issue 1(2023)
- Journal:
- Annals of the New York Academy of Sciences
- Issue:
- Volume 1521:Issue 1(2023)
- Issue Display:
- Volume 1521, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 1521
- Issue:
- 1
- Issue Sort Value:
- 2023-1521-0001-0000
- Page Start:
- 67
- Page End:
- 78
- Publication Date:
- 2023-01-11
- Subjects:
- antibody development -- biotherapeutics -- colloidal stability -- FSH -- Good Laboratory Practice (GLP)
Medical sciences -- Periodicals
Medicine -- Periodicals
Science -- Periodicals
610 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1749-6632 ↗
http://www.blackwellpublishing.com/journal.asp?ref=0077-8923&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/nyas.14952 ↗
- Languages:
- English
- ISSNs:
- 0077-8923
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1031.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26620.xml